Iteos Therapeutics Stock In The News
| ITOS Stock | USD 8.54 0.35 4.27% |
Our overall analysis of Iteos Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Iteos Therapeutics. The specific impact of Iteos Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Iteos Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Iteos Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Iteos Therapeutics Backtesting and Iteos Therapeutics Hype Analysis. For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.
Iteos |
Iteos Therapeutics Today Top News and Investor Outlook
Iteos Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Iteos and other traded companies coverage with news coverage. We help investors stay connected with Iteos headlines for the 29th of November to make an informed investment decision based on correlating the impacts of news items on Iteos Stock performance. Please note that trading solely based on the Iteos Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Iteos Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Iteos earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Iteos Therapeutics that are available to investors today. That information is available publicly through Iteos media outlets and privately through word of mouth or via Iteos internal channels. However, regardless of the origin, that massive amount of Iteos data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iteos Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iteos Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iteos Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iteos Therapeutics alpha.
Iteos Largest EPS Surprises
Earnings surprises can significantly impact Iteos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | 0.1 | 0.03 | -0.07 | 70 | ||
2021-05-13 | 2021-03-31 | -0.48 | -0.39 | 0.09 | 18 | ||
2020-11-12 | 2020-09-30 | -0.36 | -0.48 | -0.12 | 33 | ||
2024-11-05 | 2024-09-30 | -0.89 | -1.0515 | -0.1615 | 18 | ||
2024-03-06 | 2023-12-31 | -1.03 | -0.85 | 0.18 | 17 | ||
2024-05-10 | 2024-03-31 | -1.26 | -1.07 | 0.19 | 15 |
Iteos Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Iteos Therapeutics Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
22nd of November 2024
BIOTECHNOLOGY VALUE FUND L P Increases Stake in ITeos Therapeutics Inc at gurufocus.com
20th of November 2024
Insider Buying Matthew Gall Acquires 5,000 Shares of ITeos Therapeutics Inc at gurufocus.com
15th of November 2024
iTeos Therapeutics, Inc. Third-Quarter Results Heres What Analysts Are Forecasting For Nex... at simplywall.st
13th of November 2024
iTeos verkndet Finanzergebnisse fr das dritte Quartal 2024 und gibt aktuelle Geschftsinfor... at globenewswire.com
25th of October 2024
iTeos Therapeutics prsentera les donnes prcliniques et translationnelles portant sur linup... at globenewswire.com
22nd of October 2024
Acquisition by Iannone Robert of 17538 shares of Iteos Therapeutics subject to Rule 16b-3 at MacroaxisInsider
30th of September 2024
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeu - GuruFocus.com at news.google.com
16th of September 2024
HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iteos Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iteos Therapeutics' short interest history, or implied volatility extrapolated from Iteos Therapeutics options trading.
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.